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ABSTRACT 
The mechanisms of tumorigenesis of adrenocortical neoplasms have 
not been elucidated as yet. However, loss of heterozygosity at chromo- 
somal locus 17~ has been consistently observed in adrenocortical can- 
cer. p53 is a recessive tumor suppressor gene located on chromosome 
17~. Mutations in the p53 gene play an important role in the tumori- 
genesis of diverse types of human neoplasms including breast and colon 
cancers. More than 90% of all mutations discovered in such tumors 
have been detected in 4 hot spot areas that lie between exons 5 and 8. 
In contrast to wild-type ~53, mutant p53 accumulates intracellularly 
and can be easily detected by immunohistochemistry. We therefore 
investigated the frequency of p53 mutations in human adrenocortical 
neoplasms using molecular biology and immunohistochemistry tech- 
niques. Five patients with adrenocortical adenomas (5 female; ages 39- 
72 yr), 11 patients with adrenocortical carcinomas (8 female, 3 male; 
ages 15-50 yr), and two adrenocortical tumor cell lines were studied. 
After DNA extraction from frozen tumor tissue or paraffin-embedded 
material, exons 5 through 8 were amplified using the polymerase chain 
reaction and directly sequenced by the dideoxy termination method. 
Immunohistochemistry was performed on paraffin-embedded tumor 
specimens obtained during adrenalectomy using a monoclonal antibody 
reacting with both wild-type and mutant ~53. Prevalence of mutations 
was adenomas, O/5, carcinomas, 3/11, and adrenocortical cell lines, 2/ 
2. Single point mutations were detected in 3 cases (exons 5, 6, and 7, 
respectively), and rearrangements of exon 718 and 8 were found in 2 
cases. Immunohistochemistry detected strong nuclear and/or cyto- 
plasmic p53 immunoreactivity in all adrenocortical carcinomas with 
point mutations of the p53 gene but not in adenomas and carcinomas 
with the wild-type sequence or with deletion/rearrangement of the p53 
gene. We conclude that p53 plays a role in the tumorigenesis of 
adrenocortical carcinomas but is of less importance to benign adeno- 
mas. (J Clin Endocrinol Metab 78: 790-794,1994) 
B ENIGN adrenocortical adenomas are a frequent inciden- tal finding in people over 50 yr of age with a prevalence 
of 0.5-2.0% (1). In contrast, adrenocortical carcinomas are 
rare and highly malignant tumors with an incidence of 1:1.7 
million per year (2). The molecular and genetic basis of 
tumorigenesis and malignant transformation of adrenal tu- 
mors is not well understood. 
The p53 tumor suppressor gene, located on 17p (3), en- 
codes a 53-kilodalton, 393-amino acid nuclear phosphopro- 
tein involved in the control of cellular proliferation (4). 
Acquired mutations in p53 are common tumor-specific ge- 
netic changes in humans, having been identified in most 
major cancer types (5). A variety of point mutations and 
deletions of p53 have been described in human tumors (6). 
Allelic loss of 17p is often accompanied by point mutations 
at four highly preserved areas within exons 5 to 8 of the 
remaining copy of the gene, thus eliminating all wild-type 
p53 (7). Because oncogenic p53 mutations increase the sta- 
bility of p53 and result in elevated intracellular steady-state 
protein levels, p53 mutations may be identified by immu- 
nohistochemistry using p53 overexpression as a marker (8). 
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Two lines of evidence suggest a role of p53 in the tumor- 
igenesis of adrenocortical neoplasms. First, loss of heterozy- 
gosity at chromosomal locus 17p has been consistently dem- 
onstrated in adrenal carcinomas but not in adrenal adenomas 
(9). Second, germline mutations in p53 were recently iden- 
tified in families with the Li-Fraumeni syndrome (lo), a rare 
familial syndrome with an unusually high incidence of di- 
verse cancers including adrenocortical carcinomas (11). We 
thus undertook a study to determine whether mutations in 
the p53 gene are involved in the tumorigenesis of sporadic 
adrenocortical neoplasms, using immunohistochemistry and 
molecular biology techniques. 
Materials and Methods 
Zmmunohistochemistry 
Immunohistochemistry was performed on formalin-fixed paraffin- 
embedded tumor sections using the monoclonal antibody PAb 1801 (Ab 
2, Oncogene Science, Manhasset, NY), which reacts specifically with an 
epitope between amino acids 32 and 79 detecting both wild-type and 
mutant p53 (8). Briefly, 5 pm sections were enzymatically digested with 
0.1% trypsin and incubated with horse serum to block nonspecific 
binding of immunoglobulin G. After washing in phosphate buffered 
saline, sections were incubated with the primary antibody at a concen- 
tration of 10 pg/mL at room temperature for 60 min. Specific bound 
antibody was visualized by avidin-biotin complex immunoperoxidase 
staining according to the instructions of the manufacturer. Control 
sections were incubated with serially diluted primary antibody and with 
a negative control monoclonal antibody supplied by the manufacturer. 
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ABSTRACT 
The mechanisms of tumorigenesis of adrenocortical neoplasms have 
not been elucidated as yet. However, loss of heterozygosity at chromo-
somallocus 17p has been consistently observed in adrenocortical can-
cer. p53 is a recessive tumor suppressor gene located on chromosome 
17p. utations in the p53 gene play an important role in the tumori-
genesis of diverse types of human neoplasms inciuding breast and colon 
cancers. More than 90% of all mutations discovered in such tumors 
have been detected in 4 hot spot areas that He between exons 5 and 8. 
In contrast to wild-type p53, mutant p53 accumulates intracellularly 
and can be easily detected by immunohistochemistry. We therefore 
investigated the frequency of p53 mutations in human adrenocortical 
neoplasms using molecular biology and immunohistochemistry tech-
niques. Five patients with adrenocortical adenomas (5 femalej ages 39-
72 yr), 11 patients with adrenocortical carcinomas (8 female, 3 male; 
ages 15-50 yr), and two adrenocortical tumor cellHnes were studied. 
ENIGN adrenocortical adenomas are a frequent inciden-
tal finding in people over 50 yr of age with a prevalence 
of 0.5-2.0% (1). In contrast, adrenocortical carcinomas are 
rare and highly malignant tumors with an incidence of 1:1.7 
million per year (2). The molecular and genetic basis of 
tumorigenesis and malignant transformation of adrenal tu-
mors is not weIl understood. 
The p53 tumor suppressor gene, located on 17p (3), en-
codes a 53-kilodalton, 393-amino acid nuclear phosphopro-
tein involved in the control of cellular proliferation (4). 
Acquired mutations in p53 are common tumor-specific ge-
netic changes in humans, having been identified in most 
major cancer types (5). A variety of point mutations and 
deletions of p53 have been described in human tumors (6). 
Allelic loss of 17p is often accompanied by point mutations 
at four highly preserved areas within exons 5 to 8 of the 
remaining copy of the gene, thus eliminating aIl wild-type 
p53 (7). Because oncogenic p53 mutations increase the sta-
bility of p53 and result in elevated intraceIlular steady-state 
protein levels, p53 mutations may be identified by immu-
nohistochemistry using p53 overexpression as a marker (8). 
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After DNA extraction from frozen tumor tissue or paraffin-embedded 
material, exons 5 through 8 were amplified using the polymerase chain 
reaction and directly sequenced by the dideoxy termination method. 
Immunohistochemistry was performed on paraffin-embedded tumor 
specimens obtained during adrenalectomy using a monocional antibody 
reacting with both wild-type and mutant p53. Prevalence of mutations 
was adenomas, 0/5, carcinomas, 3/11, and adrenocortical cellHnes, 21 
2. Single point mutations were detected in 3 cases (exons 5, 6, and 7, 
respectively), and rearrangements of exon 7/8 and 8 were found in 2 
cases. Immunohistochemistry detected strong nuclear and/or cyto-
plasmic p53 immunoreactivity in all adrenocortical carcinomas with 
point mutations of the p53 gene but not in adenomas and carcinomas 
with the wild-type sequence or with deletionirearrangement of the p53 
gene. We conciude that p53 plays a role in the tumorigenesis of 
adrenocortical carcinomas but is of less importance to benign adeno-
mas. (J Clin Endocrinol Metab 78: 790-794, 1994) 
Two lines of evidence suggest a role of p53 in the tumor-
igenesis of adrenocortical neoplasms. First, loss of heterozy-
gosity at chromosomallocus 17p has been consistently dem-
onstrated in adrenal carcinomas but not in adrenal adenomas 
(9). Second, germline mutations in p53 were recently iden-
tified in families with the Li-Fraumeni syndrome (10), a rare 
familial syndrome with an unusuaIly high incidence of di-
verse cancers inc1uding adrenocortical carcinomas (11). We 
thus undertook a study to determine whether mutations in 
the p53 gene are involved in the tumorigenesis of sporadic 
adrenocortical neoplasms, using immunohistochemistry and 
molecular biology techniques. 
Materials and Methods 
I mmunohistochemistry 
Immunohistochemistry was performed on formalin-fixed paraffin-
embedded tumor sections using the monodonal antibody PAb 1801 (Ab 
2, Oncogene Science, Manhasset, NY), which reacts specifically withan 
epitope between amino acids 32 and 79 detecting both wild-type and 
mutant p53 (8). Briefly, 5 !-Im seetions were enzymatically digested with 
0.1 % trypsin and incubated with horse serum to block nonspecific 
binding of immunoglobulin G. After washing in phosphate buffered 
saline, sections were incubated with the primary antibody at a concen-
tration of 10 !-Ig/mL at room temperature for 60 min. Specific bound 
antibody was visualized by avidin-biotin complex immunoperoxidase 
staining according to the instructions of the manufacturer. Control 
sections were incubated with serially diluted primar  antibody and with 
a negative contro! monodonal antibody supplied by the manufacturer. 
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Positive staining was revealed as brown color. Hematoxylin was used 
as nonspecific counterstaining. 
Isolation of DNA from tissue specimens 
Adrenocortical tumor tissue was obtained at adrenalectomy from 16 
patients. DNA was isolated from 11 adrenocortical carcinomas and 5 
adrenocortical adenomas (clinical data, Table 1). In 7 cases, tumor DNA 
was extracted from paraffin-embedded sections, which were accumu- 
lated over a 30-year period. In 9 cases, both frozen (-80 C) tumor tissue 
and corresponding normal leukocyte DNA were studied. In addition, 
the DNA of the 2 currently available human adrenocortical tumor cell 
lines was studied. SW13, a nonsecretory human adrenocortical tumor 
cell line maintained in Ham’s F 10 medium with 10% fetal bovine serum, 
was received from ATCC. NCI-H-295, a human steroid-producing adre- 
nocortical tumor cell line maintained in HITES’s medium with 2% fetal 
bovine serum, was kindly provided by Dr. E. Gazdar (12). 
DNA preparation 
DNA was isolated from paraffin-embedded specimens (13), leuko- 
cytes, or frozen tumor sections obtained at surgery (14), as previously 
described. Tissue samples were derived from a central portion of the 
tumor to minimize the possibility of contamination with normal tissue. 
Representative sections of the tumor material were examined by light 
microscopy and shown to consist of more than 90% tumor cells. 
For paraffin-embedded specimens, lo-pm sections were carefully cut 
and placed in sterile Eppendorf tubes. New gloves, sterile forceps, and 
a microtome blade cleaned with xylene between each sample were used 
for every tumor block to avoid cross contamination and to minimize 
preparation artifacts (13). All paraffin-embedded tissue samples had 
been fixed in buffered formalin. In a previous study we have shown 
that polymerase chain reaction (PCR) products of 600-base pair length 
could be successfully amplified with these techniques using the same 
tumor blocks but a different oncogene (15). 
PCR amplification of genomic DNA 
PCR (16) was used to amplify DNA fragments including exons 5 
through 8, which contain the four hot spot regions accounting for more 
than 90% of all mutations found in human tumors. Aliquots of 1 and 
10 PL DNA preparation from paraffin-embedded tissues or 1 rg DNA 
from frozen tissue or leukccyte DNA were amplified in a 100 rL PCR 
mixture containing deoxynucleotide triphosphates (200 pmol/L each), 
upstream and downstream oligonucleotide primers (0.3 mmol/L each), 
0.01% gelatin, 50 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 1.5 mmol/ 
L MgCl2, and 2.5 U Taq polymerase (Perkin Elmar Cetus, Norwalk, CT). 
The following primers were used: exon 5: 5’-TGT TCA CTT GTG CCC 
TGA CT-3’ and 5’-AGC AAT CAG TGA GGA ATC AG-3’; exon 6: 5’- 
TGG TTG CCC AGG GTC CCC AG-3’ and 5’-GGA GGG CCA CTG 
ACA ACC A-3’; exon 7: 5’.CTT GCC ACA GGT CTC CCC AA-3’ and 
5’.AGG GGT CAG CGG CAA GCA GA-3’; exon 8: 5’ TTG GGA GTA 
GAT GGA GCC T-3’ and 5’.AGT GTT AGA CTG GAA ACT TT-3’ 
(17, 18). Special precautions were taken to avoid contamination of the 
PCR samples. In all PCR experiments, samples containing no DNA were 
included as negative controls. The amplification protocol consisted of 
denaturation at95 C for 5 min followid by 30-4b cycles consisting of 
annealing at 55 C for 1% min, primer extension at 72 C for 1% min and 
denaturason at 94 C for 1 mi;. All amplified samples were examined 
by agarose gel electrophoresis to confirm successful amplification of 
each of the exons of ~53. 
Direct sequencing of the PCR product 
Single-stranded DNA was synthesized using as template the product 
of the symmetric PCR described above. For the amplification of only 
one DNA strand selectively, a nested sense or an antisense primer (50 
pmol) was added, and the asymmetric PCR was carried out for 20 cycles 
(19). Single-stranded DNA was separated from nonincorporated nucle- 
otides anh primers by filtration through Ultrapure MC filiers (Millipore, 
Bedford, MA). The retentate was lvophilized at room temoerature and 
redissolved before use in the DNA sequencing reaction. T’he following 
nested primers were used: exon 5: 5’-TTC AAC TCT GTC TCC TTC 
CT-3’ and 5’-CAG CCC TGT CGT CTC TCC AG-3’; exon 6: 5’.GCC 
TCT GAT TCC TCA CTG AT-3’ and 5’-TTA ACC CCT CCT CCC 
AGA GA-3’; exon 7: 5’-AGG CGC ACT GGC CTC ATC TT-3’ and 5’- 
TGT GCA GGG TGG CAA GTG GC-3’; exon 8: 5’-TTC CTT ACT 
GCC TCT TGC TT-3’ and 5’-AGG CAT AAC TGC ACC CTT GG-3’ 
(18). Using the dideoxy-chain-termination method of Sanger (20), the 
PCR product was sequenced (T7-DNA polymerase, Sequenase 2.0, 
United States Biochemicals, Cleveland, OH) with [ru35S]-dATP and run 
on a 6% denaturing polyacrylamide gel. Autoradiography was per- 
formed with Kodak XAR 2 films (Kodak, Rochester, NYI. 
To exclude cross contaminatibn of mutated genes ‘in the reaction 
buffers, primers, or genomic DNA preparation, each mutation was 
confiied by sequencing both a second PCR sample and the coding 
and noncoding strands of the products. 
Results 
Expression of p53 in adrenocortical neophms 
No p53 protein was detected by immunohistochemistry in 
any of the adrenocortical adenomas, in normal adrenal cortex 
adjacent to the adenomas (n = 3), or in 6 of 11 (55%) 
TABLE 1. Clinical data of the patients studied 
Patient no. Sex Age Clinical presentation Tumor size (cm) Histolo~ DNA source 
1 F 
2 
3 F 
4 F 
5 M 
6 M 
7 
8 : 
9 F 
10 F 
11 M 
12 F 
13 F 
14 
15 F 
16 F 
15 
24 
14 
50 
23 
27 
25 
29 
22 
27 
37 
72 
40 
67 
39 
49 
Gushing’s syndrome, virilization 25 x 17 x 8 
Nonsecieto-& tumor 1x2 
Cushine’s svndrome. virilization 
Conn s&I&me 
7X4x2 
9X8X7 
Virilization 6~5x2 
Feminization 36 x 21 x 15 
MEN I, Cushing syndrome 9X8X5 
Nonsecretory tumor 8X6X1 
CushingTs syndrome 122 6X lo- 
Virilization 17 cm diam. 
Feminization 30 x 16 x 10 
Nonsecretory tumor 4X2X2 
Conn syndrome 2X3x3 
Gushing’s syndrome 2.5 cm diam. 
MEN I, Cushing’s syndrome 4X4X3 
Cushing’s syndrome 2.5 cm diam. 
Liver metast., adrenal carcinoma 
Lung metast., adrenal carcinoma 
Metastatic adrenal carcinoma 
Adrenal carcinosarcoma 
Metastatic adrenal carcinoma 
Metastatic adrenal carcinoma 
Adrenal carcinoma 
Brain metast., adrenal carcinoma 
A&enaI carcincxna- 
Adrenal carcinoma 
Metastatic adrenal carcinoma 
Adrenocortical adenoma 
Adrenocortical adenoma 
Aclrenocortical adenoma 
Adrenocortical adenoma 
Adrenocortical adenoma 
Frozen tissue 
Frozen tissue 
Frozen tissue 
Frozen tissue 
Paraffin 
Paraffin 
Paraffin 
Paraffin 
?craffk 
Paraffin 
Paraffin 
Frozen tissue 
Frozen tissue 
Frozen tissue 
Frozen tissue 
Frozen tissue 
F, female; M, male; metast., metastasis; diam., diameter. 
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TABLE 2. Mutational spectrum of ~53 in human adrenocortical carcinomas and cell lines 
Patient no. 
p53 overexpression 
(immunohistochemistry) DNA source Mutation 
EXOll Codon 
Nucleotide Amino acid 
exchange exchange 
SW13 
NCI-H-295 
4 
5 
6 
nd 
nd 
++ 
++ 
Cell line Point mutation 6 193 CAT + TAT His + Tyr 
Cell line Insertion 8 
Frozen tissue Point mutation I 248 CGG + TGG Arg + Trp 
Paraffin Point mutation 5 151/152 CCC + GCC Pro + Ala 
CCG + GCG Pro + Ala 
Paraffin Deletion/rearrangment 718 
Arg, arginine; Trp, tryptophan; Pro, proline; His, histidine; Tyr, tyrosine; nd, not determined. 
FIG. 1. (Left) ~53 overexpression in an 
adrenocortical carcinoma (x20) showing 
strong cytoplasmic staining. (Right) 
Negative control section (x20). 
carcinomas. Three adrenal cancer specimens (27%) had de- 
tectable cytoplasmic or nuclear p53 immunoreactivity but in 
only a small percentage of the malignant cells (<lo%). Pos- 
itively stained cells in this category were generally localized 
in one area of the section but were not closely clustered. Two 
carcinomas (18%; one metastatic adrenal carcinoma, one 
adrenosarcoma) exhibited strong cytoplasmic/nuclear p53 
immunoreactivity throughout the tumor, suggesting very 
high levels of p53 expression in these tissues (Fig. 1). 
Sequence ofp53 exon 5 to 8 in adrenocortical tumors/cell lines 
None of the adrenal adenomas had p53 mutations in exons 
5 through 8. In contrast, 3 of 11 adrenal carcinomas (27%) 
and both adrenocortical tumor cell lines had p53 mutations 
of the highly conserved regions within exons 5-8. In three 
cases a point mutation was detected, which altered the coding 
region of the gene (Table 2 and Fig. 2). The mutations were 
confirmed by sequencing a second PCR sample of each 
tumor. In each case the mutation caused a nonconservative 
amino acid substitution resulting in the production of an 
abnormal p53 protein with a probably altered half-life and 
biological function. In two cases, the genomic sequence of 
p53 was grossly altered resulting in absence or truncation of 
the p53 protein. In one carcinoma, exon 7 was completely 
deleted and could not be amplified by means of PCR. Exon 
8 of the same tumor showed a large 900-base pair insertion 
resulting in the amplification of an abnormal DNA fragment 
by PCR. In the second case, the NCI-H-295 adrenal cancer 
cell line, a 1200-base pair insertion was found in exon 8 (Fig. 
3). The rearrangement of the p53 gene in this case was 
confirmed by Southern blot. 
Discussion 
Tumorigenesis has been assumed to result from molecular 
alterations that disrupt normal cell growth and terminal 
Tumor DNA Normal lymphocytic DNA 
G A T C G A T C 
T 
Leu194T 
T 
Tyr f93 A 
I 
G 
Gln192A 
C 
T 
TLeu194 
C 
T 
AHis193 
C 
G 
AGIn 
C 
FIG. 2. (Left) Sequencing analysis of an amplified genomic fragment 
(exon 7) of the p53 gene from the adrecortical carcinoma cell line SW 
13, showing a point mutation at codon 193. (Right) Lymphocyte DNA 
from a normal subject containing only the wild-type sequence of ~53 
for comparison. 
differentiation. Mutations in the p53 tumor suppressor gene 
are common genetic alterations in human cancers and have 
been found mainly in 4 hot spot regions within exons 5 to 8 
and between amino acids 132 and 286 (5, 6). Wild-type p53 
is expressed in normal cells and appears to be involved in 
the control of cellular growth and proliferation, whereas 
alterations in the p53 gene, such as point mutations, allelic 
loss, rearrangements, and deletions result in tumor forma- 
tion. Mutant p53 has transforming activity in vitro and fails 
to bind to the simian virus 40 tumor antigen (21). However, 
the mutants do form stable complexes with hsp70 (22), a 
constitutively expressed member of the heat shock protein 
family, and this may be the reason for the increased half-life 
and elevated steady-state levels of the mutant proteins in 
tumor cells (8). 
Few studies have investigated the role of p53 in endocrine 
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FIG. 3. PCR amplification of exon 8 showing an abnormal DNA frag- 
ment in the adrenocortical cancer cell line NC1 H 295 (lane b) compared 
to normal amplification products in lymphocyte DNA from a normal 
subject or the adrenocortical cancer line SW13 (lanes a and c, respec- 
tively). Lone d: size marker 4X174. 
neoplasms. Yoshimoto et al. (23) studied 134 primary endo- 
crine tumors, including pituitary adenomas, thyroid and 
parathyroid tumors, endocrine pancreatic tumors, pheo- 
chromocytomas, and adrenocortical adenomas using single- 
strand conformation polymorphism analysis. According to 
their results, p53 mutations play a role in a limited number 
of parathyroid adenomas and thyroid carcinomas but not in 
adrenocortical neoplasms. Interestingly, Yoshimoto et al. (23) 
did not detect a mutation in the SW 13 adrenal carcinoma 
cell line, which was shown in this study to have a mutation 
at codon 193 changing histidine to tryptophan. This differ- 
ence may be explained by a lower sensitivity of single-strand 
conformation polymorphism analysis in detecting point mu- 
tations compared to direct sequencing of the PCR amplifi- 
cation product which was used in this study. Recently, Fagin 
et al. (24) reported a high incidence of p53 mutations in 
anaplastic thyroid carcinomas but not in more differentiated 
thyroid tumors. We identified mutations in 3 of 11 (27%) 
adrenocortical carcinomas and in both carcinoma cell lines. 
We found point mutations at codons 151/152,193, and 248, 
which were close to or within the four highly conserved 
regions of the gene and have been previously reported in 
other human cancers. These mutations resulted in noncon- 
servative amino acid substitution, likely to be of functional 
significance. In two other cases, large insertions or re- 
arrangements of exons 7 and 8 were observed, altering the 
reading frame of the coding sequence of ~53, resulting prob- 
ably in the generation of altered mRNAs with absence or 
truncation of the p53 protein. 
As expected, both adrenocortical tumor specimens con- 
taining point mutations showed p53 overexpression by im- 
munohistochemistry, demonstrating a good correlation be- 
tween the immunohistochemical data and the DNA abnor- 
mality. In contrast, in the carcinoma with a grossly abnormal 
p53 gene (case 6) p53 immunoreactivity was not detectable 
by immunohistochemistry, probably due to lack of p53 
expression or expression of a truncated protein with altered 
immunogenity. The other tumors with scattered or absent 
p53 immunoreactivity showed only the wild-type sequence 
of p53. 
Whereas p53 mutations are important in the carcinogene- 
sis of adrenocortical cancer, they do not seem to play a major 
role in the formation of adrenal adenomas. It was recently 
suggested that G proteins, membrane-bound heterotrimeric 
polypeptides that couple receptor signals to second messen- 
ger systems like CAMP (25,26), might be involved in adrenal 
tumor formation, Point mutations at 2 codons of the highly 
preserved a-chain of Gi, the adenylcyclase-inhibiting G pro- 
tein, resulting in constitutively activated Gai2, were reported 
in 2 of 10 adrenocortical adenomas, suggesting a potential 
role of this isoform in the genesis of these tumors (27). We 
reevaluated the frequency of Gai2 mutations in 10 adreno- 
cortical adenomas and were unable to confirm these findings 
(15). None of our tumors studied contained point mutations 
in the previously reported hot-spot regions. These findings, 
together with the low prevalence of p53 mutations in adrenal 
adenomas reported here, suggest that the mechanism of 
tumorigenesis in benign adrenocortical tumors involves on- 
cogenic mutations of other cell constituents. 
Acknowledgements 
We would like to thank Dr. E. Gazdar for providing the NCI-H-295 
adrenocortical cancer cell line and Jan Sakol for assistance in collecting 
the tumor specimens. 
References 
1. Copeland PM. 1983 The incidentally discovered adrenal mass. Ann 
Int Med. 98:940-945. 
2. Nader S, Hickey RC, Sellin RV, Samann NA. 1983 Adrenocortical 
carcinoma: a study of 77 cases. Cancer. 52707-713. 
3. Benchimol S, Lamb P, Crawford LV, et al. 1985 Transformation 
associated p53 protein is encoded by a gene on human chromosome 
17. Somatic Cell Mol Genet. 11:505-509. 
4. Levine AJ, Momand J, Finlay CA. 1991 The p53 tumour suppressor 
gene. Nature. 351:453-356. 
5. Fromentel CC, Soussi T. 1992 tp53 tumor suppressor gene: a model 
for investigating human mutagenesis. Genes Chromosomes & Can- 
cer. 4:1-15. 
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991 P53 
mutations in human cancer. Science. 253:49-53. 
7. Baker SJ, Preisinger AC, Jessup JM, et al. 1990 p53 gene mutations 
occur in combination with 17~ alleleic deletions as late events in 
colorectal tumorigenesis. Cancer Res. 50:7717-7722. 
8. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. 1991 Genetic 
basis for p53 overexpression in human breast cancer. Proc Nat1 
Acad Sci USA. 88:5006-5010. 
9. Yano T, Linehan M, Anglard P, et al. 1989 Genetic changes in 
human adrenocortical carcinoma. J Nat1 Cancer Inst. 81:518-523. 
10. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. 1990 Germ- 
line transmission of a mutated p53 gene in a cancer-prone family 
with Li-Fraumeni syndrome. Nature. 348:747-749. 
11. Li FP, Fraumeni Jr JF. 1969 Soft-tissue sarcomas, breast cancer, 
and other neoplasms: a familial syndrome? Ann Int Med. 71:747- 
752. 
12. Gazdar AE, Oie HE, Shackleton CH, et al. 1990 Establishment and 
characterization of a human adrenocortical carcinoma cell line that 
express multiple pathways of steroid biosynthesis. Cancer Res. 
50:5488-5496. 
13. Wright DK, Manos MM. 1990 Sample preparation from paraffin- 
 at UBM Klinikum Innenstadt on October 30, 2008 jcem.endojournals.orgDownloaded from 
p TATIONS  RENAL EOPLASMS 1  
  
I:::::::: 1353 1(178 8  
 
 
IG.  lification  no  ing  ormal A -
ent  e enocortical er li ne I (   pared 
t  r al lification roducts  ly phocyte   no al 
t  e ocortical er ine 3 w es n n d , · 
ely). nne  r  rker Q!>X174. 
l sms. t l. t   i ary 
u ing tuitary no as, id  
id t
, r cortie l as i  i l -
e lion orphis  l i . e r ing 10
I lt , ay  I ite
id no as  id   
eorti l s. r ly, t l.  
l on   l  
l ich  10   
 10 ptophan. i e -
  i ty i
 rp is  alysis  
  quencing  pe pli
e  ch  t tl i  
t l. )  
l ti  roid r i s   ferentiated 
r id ied  1 ) 
eorti l   r i  l  . 
ou   s   193, , 
c  d e 10  thin  ly 
i    ously   
l  rs.  ons l
 i i  ti o , e  10   onal 
c .   ses, r
nts  r d, l  
i  quence  p l
I r ti  l s th sence 
r on  . 
t ,  r corti l r ci ens 
n   i   
i t  l
i l  
l . th  sl  r l 
  e  re ivity  t t bl  
 l y 10   
si   si n   eate   th l  
ty.  th t r d ent 
S e ivity   ld-type ence 
 S
ta t rci ne-
is  r  cer, I  em 10 ay  j
 r ion l as.   t
sted  s t
e tides  t i ls 10 cond ssen-
t s c   26),   olved l 
r r a ion. t o s t    
 d e-i ting 
l lively t  
   rt as, esting  t
j  nesis  ).  
r e     
 as   i
e  t i l 
sly  i . e 
 ith   r l 
s  ggest  anism 
i  i r nocorti l lves 
r nie l l  li . 
cknowledgements 
e ould ike 10 I ank . . ar  oviding I I-H·295 
ocorlicat er t  ine   i tlecting 
I  or ens. 
rences 
L peland .  e dentally s vered enal . n 
 .:!. :940- 945. 
ader , ickey , lin , ann . renocortical 
no a: l  s.  :707- 713. 
. enchimol 5 a b , a ford ,  sformation 
i l  S  r tein i  ed   e  an r osome 
. lic  ol .  - 509. 
. evine , omand , inlay .  e  t our ressor 
ture.  :453- 356. 
. romentel , ssi .  I  l or ess r   l 
 i estigating an tagenesis.  osomes : 
-15. 
. ISlein , ransky 0  ogelstein  ris e  
Ulations  an d  9- 53. 
. aker , eisinger ,  , l .    Ulations 
  bination ilh p eleie tions  te l
rectal origene is. er . 17- 722 . 
. Oa idoff , umphrey , 1ehart O arks . c 
s  pression  an t l 
cad ei . :5006- 5010. 
. ano , inehan o nglard  O l. tic es 
an ocorticat noma. , ll  ! . :518-523. 
. vaslava u  rollo k  81altner ang . -
ne s i sion 01 lated  e  -prone y 
ilh -Fraumeni rome. ture. :747- 749. 
. i raumeni .  -ti sue  
 er o las s: lial ro e? nn e . 7-
2. 
. zdar , ie , leton , l .  lishmenl  
terization an ocortical noma ll e i
 ltiple lhways l id s nthesis. r s. 
:5488-5496. 
. righl , ilnos .  Ie eparation (  in-
794 REINCKE ET AL. JCE8zM.1334 
Vol78.No3 
14. 
15. 
16. 
17. 
18. 
19. 
embedded tissues. In: lnnis MA, Gelfand DH, Sninsky JJ, White IJ, 
eds. PRC protocols: a guide to methods and applications. San Diego: 
Academic Press; 153-159. 
Sambrook J, Fritsch EF, Maniatis T. 1989 Molecular Cloning. A 
Laboratory Manual. 2nd ed. Cold Spring Harbor, NY; 9.16-9.23. 
Reincke M, Karl M, Travis W, Chrousos GP. 1993 No evidence 
for oncogenic mutations in guanine nucleotide binding proteins of 
human adrenocortical neoplasms. J Clin Endocrinol Metab. 
77:1419-1422. 
Saiki RK, Gelfand DH, Stoffel S, et al. 1988 Primer-directed 
enzymatic amplification of DNA with a thermostable DNA polym- 
erase. Science. 239:487-491. 
Lamb P, Crawford L. 1986 Characterization of the human p53 
gene. Mol Cell Biol. 6:1379-1385. 
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991 
Mutational hotspots in the p53 gene in human hepatocellular car- 
cinoma. Nature. 350:427-428. 
McCabe PC. 1990 Production of single-stranded DNA by asym- 
metric PCR. In: lnnis MA, Gelfand DH, Sninsky JJ, White TJ eds. 
PCR protocols: a guide to methods and applications. San Diego: 
Academic Press; 76-84. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
Sanger F, Nicklen S, Coulson AR. 1977 DNA sequencing with 
chain terminating inhibitors. Proc Nat1 Acad Sci USA. 74:5463- 
5467. 
Jenkins JR, Rudge K, Currie GA. 1984 Cellular immortalization by 
a cDNA clone encoding the transformation-associated phosphopro- 
tein ~53. Nature. 312:651-654. 
Finlav CA, Hinds PW, Levine AI. 1988 Activating mutations for 
transformation by p53 produce a gene product that &rns an hsc70- 
~53 comolex with an altered half-life. Mol Cell Biol. 8:531-539. 
koshimdto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. 
1992 Role of p53 in endocrine tumorigenesis: mutation detection by 
polymerase chain reaction-single strand conformation polymor- 
phism. Cancer Res. 52:5061-5064. 
Fagin JA. 1992 Molecular defects in thyroid gland neoplasia. J Clin 
Endocrinol Metab. 75:1398-1400. 
Bourne HR, Sanders DA, McCormick F. 1990 The GTPase super- 
family: a conserved switch for diverse cell functions. Nature. 
348:125-132. 
Simon MI, Strathmann MP, Gautum N. 1991 Diversity of G 
proteins in signal transduction. Science. 252:802-808. 
Lyons J, Landis CA, Harsh G, et al. 1990 Two G protein oncogenes 
in human endocrine tumors. Science. 249:655-659. 
 at UBM Klinikum Innenstadt on October 30, 2008 jcem.endojournals.orgDownloaded from 
4 INCKE T . E & M·1994 
oI7S·No3 
bed ed ti sues. In: I nis A, elfand H, insky H, hite IJ, 
s. C rotocols:  ide  ethods d plications. n iego: 
cademic re s; 53-159. 
. ambrook J, ritsch F, aniatis . 89 olecular lo ing.  
aboratory anual. nd . old ring arbor, ; .16-9 23. 
. eincke , arI , ravis , hrousos P. 93 o idenee 
f r cogenic utations in a ine cleotide inding roteins f 
human adrenocortical neoplasms. J lin Endocrinol etab. 
77:1419-1422. 
. Saiki RK, elfand H, StoffelS, et Al. 1988 Primer-directed 
enzymatic a plification of NA ith a thermostable NA polym-
erase. Seience. 239:487-491. 
17. Lamb P, Crawford L. 1986 Characterization of the human p53 
gene. Mol Cell Biol. 6:1379-1385. 
18. Hsu IC, MetcaU RA, Sun T, Welsh JA, Wang NJ, Harris Ce. 1991 
utational hotspots in the p53 gene in human hepatocellular car-
einoma. Nature. 350:427-428. 
19. McCabe PC. 1990 Production of single-stranded DNA by asym-
metrie PCR. In: Innis MA, Gelfand DH, Sninsky H, hite TJ eds. 
PCR protocols: a guide to methods and applications. San Diego: 
Academic Press; 76-84. 
. anger , icklen 5, oulson R. 7 A uencing ith 
ain t rminating i hibitors. roc atl cad ei A. 4:5463-
67. 
. nkins , udge , urrie . 84 llular i mort lization  
a c NA clone e coding t e transformation-associated hosph pro-
tein p 3. ature. 12:651-654. 
. Finlay , inds P , Levine J. 1988 ctivating utations for 
transformation by p53 produce a gene product that forms an hse70-
p53 eomplex ith an altered half-life. ol ell iol. 8:531-539. 
. Yoshimoto , I hana , ukuda , no , ito 5, Itakura . 
1992 Role of p53 in endocrine tu origenesis: utation detection by 
polymerase chain reaction-single strand conformation polymor-
phism. ancer es. 52:5061-5064. 
24. Fagin JA. 1992 olecular defects in thyroid gland neoplasia. J Clin 
Endocrinol etab. 75:1398-1400. 
25. Bourne HR, Sanders DA, cCormick F. 1990 The GTPase super-
fa ily: a conserved switeh for diverse cell funetions. Nature. 
348:125-132. 
26. Simon MI, Strathmann MP, Gautum N. 1991 Diversity of G 
proteins in signal transduction. Science. 252:802-808. 
27. Lyons J, Landis CA, Harsh G, et Al. 1990 Two G protein oneogenes 
in human endocrine tumors. Science. 249:655-659. 
